MDM2 antagonist nutlin-3a sensitizes tumors to V-ATPase inhibition

Treating cancer is one of the big challenges of this century and it has become evident that single chemotherapeutic treatment is rarely effective. As tumors often carry multiple mutations using combination therapy which addresses different targets seems therefore more beneficial. One of the most frequently mutated genes in tumors is the tumor suppressor p53. Significant work has been put in the development of p53 activators, which are now in clinical studies against diverse cancers. Recently, we could show that inhibition of V-ATPase, a multisubunit proton pump, by archazolid induces p53 protein levels in cancer cells.

Source: Molecular Oncology - April 25, 2016 Category: Cancer & Oncology Authors: Lina S. Schneider, Melanie Ulrich, Thorsten Lehr, Dirk Menche, Rolf M üller, Karin von Schwarzenberg Source Type: research